Drug Topics

JUNE 11, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Health and Personal Care Stores 315

Health and Personal Care Stores Community Pharmacies Independent Pharmacies Communication 315

Pharmacy Times

JUNE 11, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

Specialty Pharmacies 65

Specialty Pharmacies Hospitals Compounding Pharmacies FDA 65

Med Ed 101

JUNE 11, 2025

Trimethoprim-sulfamethoxazole (Bactrim) is a commonly prescribed antibiotic for urinary tract and other infections. However, it’s also associated with several clinically significant drug interactions that can lead to serious patient harm if overlooked. Here are my top five Bactrim drug interactions you need to watch for—especially in the elderly and patients on multiple medications.

52

52

Pharmacy Times

JUNE 11, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

Specialty Pharmacies 73

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy 73

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharma Marketing Network

JUNE 11, 2025

The pharmaceutical industry has long been revered for its scientific breakthroughs, drug innovation, and commitment to patient health. Yet when it comes to modern marketing strategy, some argue the industry is trailing behind. While retail, finance, and tech sectors have embraced real-time analytics, AI personalization, and omnichannel messaging, pharma marketing still clings to outdated models.

FDA 52

FDA 52

Pharmacy Times

JUNE 11, 2025

Retail pharmacies are undergoing a meaningful transformation into accessible, community-based health care hubs by expanding clinical services, embracing value-based care, and addressing gaps in access, technology, and reimbursement.

Community Pharmacies 112

Community Pharmacies 112

Pharmacy Times

JUNE 11, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

FDA 73

FDA Compounding Pharmacies Immunization Hospitals 73

PharmaShots

JUNE 11, 2025

Shots: The US FDA has approved the IND application of NVC-001 to treat LMNA-related dilated cardiomyopathy (LMNA DCM), enabling a P-I/II trial to start in early 2026 Preclinical studies showed that NVC-001 significantly improved survival and cardiac function. They planned a P-I/II trial, a 52-week, open-label, multicenter ascending-dose study to assess the safety, tolerability, and preliminary efficacy of one-time IV NVC-001 in adults with LMNA-DCM NVC-001 is an AAV-based gene therapy for LMNA-D

Labelling 59

Labelling FDA 59

Pharmacy Times

JUNE 11, 2025

The expansion marks glecaprevir/pibrentasvir as the first and only indicated direct-acting antiviral approved for acute hepatitis C virus (HCV) infection.

FDA 65

FDA 65

PharmaShots

JUNE 11, 2025

Shots: Philochem and RayzeBio (BMS) entered into a development and commercialization agreement under which Philochem granted RayzeBio exclusive worldwide rights to develop, manufacture, and commercialize its radiopharmaceutical agent OncoACP3 for prostate cancer Under the agreement, Philochem will receive $350M up front and is eligible for up to $1B in development, regulatory, and commercial milestones, plus mid-single to low double-digit royalties for both therapeutic and diagnostic agents of

59

59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JUNE 11, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

FDA 73

FDA Compounding Pharmacies Immunization Specialty Pharmacies 73

Pharmafile

JUNE 11, 2025

BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small molecule design specialist Silicogenix (SGX) to accelerate polypharmacology and non-traditional drug development. The collaboration will combine BioDuro’s drug discovery capabilities with SGX’s design frameworks to streamline the development of complex therapeutics.

59

59

Drug Topics

JUNE 11, 2025

Whether it is a kitchen mishap or backyard injury, pharmacists are key in helping patients choose the right OTC first aid products for fast, effective care.

247

247

Pharmaceutical Commerce

JUNE 11, 2025

In the final part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, illustrates how data-driven insights can support PBMs and healthcare leaders in negotiating fairer drug prices?

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PhRMA

JUNE 11, 2025

The United States is the epicenter of groundbreaking biopharmaceutical research, and maintaining this leadership requires investment in the future scientific workforce. This year marks the 60th year that the PhRMA Foundation has helped build and train this workforce. A 501(c)(3) nonprofit, the Foundation provides grants and fellowships to graduate students, postdoctoral trainees and new faculty members conducting novel research, setting the stage for tomorrow’s biomedical breakthroughs tha

100

100

Pharmacy Times

JUNE 11, 2025

A multidisciplinary, technology-enhanced approach supported by executive leadership is essential for effective drug diversion surveillance and regulatory compliance in health systems.

65

65

Pharmaceutical Technology

JUNE 11, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents FDA Communication Hospitals 52

PharmTech

JUNE 11, 2025

News All News Bio/Pharma News Publications All Publications PharmTech PharmTech Europe Resources Marketplace ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management Peer-Reviewed Research PharmTech Products Pharma Insights Sponsored Podcasts Sponsored Videos Sponsored eBooks Whitepapers Webcasts Multimedia All Videos Ask the Expert Behind The Headlines Buy, Sell, Hold Drug Digest Videos Drug Solutions Podcast Peer Exchange Sexy Science Tech Talk Conference Conference Coverage Confer

Dosage 52

Dosage Packaging Vaccines Compounding 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

JUNE 11, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Communication 52

Communication Hospitals Packaging Insurance 52

PharmaVoice

JUNE 11, 2025

Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve

Packaging 179

Packaging Documentation 179

Pharmaceutical Technology

JUNE 11, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Communication 52

Communication Hospitals Packaging Insurance 52

European Pharmaceutical Review

JUNE 11, 2025

The US Food and Drug Administration (FDA) has expanded its approval of the first direct acting antiviral (DAA) therapy to treat acute hepatitis C virus infection in eight weeks with a 96 percent cure rate. Mavyret ® (glecaprevir/pibrentasvir) is now indicated for adults and paediatric patients aged three years and over who have acute or chronic forms of the viral infection with or without cirrhosis or with compensated cirrhosis.

FDA 52

FDA 52

Pharmaceutical Technology

JUNE 11, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

FDA 52

FDA Communication Hospitals Packaging 52

PharmaShots

JUNE 11, 2025

Shots: The US FDA has approved Ibtrozi (taletrectinib) for treating locally advanced or metastatic ROS1+ NSCLC Approval was based on the P-II [ TRUST-I (China) & TRUST-II (global)] studies assessing Ibtrozi monotx. in 173 & 164 pts with ROS1+ NSCLC, respectively TRUST-I showed a cORR of 90% in TKI-naïve pts, with longest DoR of 46.9mos. & ongoing (mFU: 40mos.) while TRUST-II showed 85% cORR with DoR of 30.4mos. & ongoing, as of Oct 2024 (mFU: 19mos.); mDoR was not yet reached for

Labelling 59

Labelling FDA 59

Pharmafile

JUNE 11, 2025

Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, Nashville, US, on 7 June, highlighting the impact of Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis (AD) and skin of colour. The open-label trial enrolled 120 patients with Fitzpatrick skin types IV–VI, including Black, […] The post Dupixent improves symptoms in patients with skin of colour, study shows appeare

Labelling 59

Labelling 59

Pharmaceutical Technology

JUNE 11, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Communication 52

Communication Hospitals Packaging Insurance 52

Fierce Healthcare

JUNE 11, 2025

Capital Rx says the acquisition now allows its members to benefit from a seamless, unified medical and pharmacy claims platform.

57

57

European Pharmaceutical Review

JUNE 11, 2025

The US Food and Drug Administration (FDA) has expanded its approval of the first direct acting antiviral (DAA) therapy to treat acute hepatitis C virus infection in eight weeks with a 96 percent cure rate. Mavyret ® (glecaprevir/pibrentasvir) is now indicated for adults and paediatric patients aged three years and over who have acute or chronic forms of the viral infection with or without cirrhosis or with compensated cirrhosis.

FDA 52

FDA 52

Drug Topics

JUNE 11, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Immunization 315

Immunization Vaccines Independent Pharmacies Specialty Pharmacies 315

PharmaShots

JUNE 11, 2025

Skip to content Skip to footer NEWS TOP 20 INSIGHTS INSIGHTS+ THOUGHTSPOT INTERVIEWS VIEWPOINTS EXCLUSIVE SPOTLIGHT EVENTS MAGAZINE Subscribe Now NEWS TOP 20 INSIGHTS INSIGHTS+ THOUGHTSPOT INTERVIEWS VIEWPOINTS EXCLUSIVE SPOTLIGHT EVENTS MAGAZINE Login or Register Home Features Blog Page Blog Band Blog Standard Blog Classic Blog Classic with sidebar Blog Portfolio Blog Portfolio with sidebar Pages About 1 About 2 Subscribe Now Typography Authors 404 Page Video Playlist Video Playlist 1 Video Pla

FDA 52

FDA 52

Pharmacy Times

JUNE 11, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

Compounding Pharmacies 102

Compounding Pharmacies Community Pharmacies Hospitals Vaccines 102

Drug Topics

JUNE 11, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Specialty Pharmacies 315

Specialty Pharmacies Compounding Independent Pharmacies Communication 315

Fierce Pharma

JUNE 11, 2025

Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York drugmaker and two other pharma giants in a lung cancer field.

70

70